Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 4861570, 6 pages
Review Article

Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review

1Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland
2Department of Clinical Oncology, Oncology Center in Opole, Opole, Poland
3Department of Oncologic Pathology and Prophylactics, Poznan University of Medical Sciences and Greater Poland Cancer Center, Poznan, Poland

Correspondence should be addressed to Marlena Janiczek; moc.liamg@anelram.kezcinaj

Received 7 June 2017; Revised 4 September 2017; Accepted 14 September 2017; Published 3 October 2017

Academic Editor: Jiaming Liu

Copyright © 2017 Marlena Janiczek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prostate cancer treatment is currently based on surgical removal, radiotherapy, and hormone therapy. In recent years, another therapeutic method has emerged—immunological treatment. Immunotherapy modulates and strengthens one’s immune responses against cancer. Neoplastic cells naturally escape from the control of the immune system, and the main goal of immune therapy is to bring the control back. Satisfying outcomes after treatment of advanced melanoma and lung cancer suggest a great potential of immunotherapy as an approach for other tumors’ treatment, especially in patients primarily introduced to palliative care. After initial clinical trials, immunotherapy seems to have different side effects than chemotherapy. Prostate cancer was the first neoplasm in which a specific vaccine significantly improved survival. There is a tremendous potential for synergistic combinations of immunotherapy with conventional cancer treatments. A combination of several drugs or methods can be a key in radical treatment of metastatic prostate cancer as demonstrated by preliminary studies.